Clinical Trials
28
Active:0
Completed:7
Trial Phases
4 Phases
Phase 1:11
Phase 2:3
Phase 3:7
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (39.3%)Not Applicable
7 (25.0%)Phase 3
7 (25.0%)Phase 2
3 (10.7%)Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Not Applicable
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: HDM1002 200 mgDrug: HDM1002 400 mgDrug: Placebo
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Target Recruit Count
- 360
- Registration Number
- NCT07193459
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing Municipality, China
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Not Applicable
Recruiting
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Drug: Rituximab or Rituximab biosimilar
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Target Recruit Count
- 97
- Registration Number
- NCT07124936
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Not Applicable
Not yet recruiting
- Conditions
- T2DM (Type 2 Diabetes Mellitus)CKD - Chronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-12
- Target Recruit Count
- 1244
- Registration Number
- NCT07116928
- Locations
- 🇨🇳
Shanghai sixth People's Hospital, Shanghai, Shanghai, China
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
Not Applicable
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: HDM1005 1Drug: HDM1005 2Drug: HDM1005 3Drug: HDM1005 4Drug: PlaceboDrug: Dulaglutide 1.5 MG
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-17
- Target Recruit Count
- 216
- Registration Number
- NCT07109700
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of HDM2012 in Patients With Advanced Solid Tumor
Not Applicable
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: HDM2012
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-08
- Target Recruit Count
- 129
- Registration Number
- NCT07100249
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found